$ENTO
Entero Therapeutics Inc Stock $ento

$ento Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000141057822002519 Filed on August 15, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.904M	$2.499M	$4.406M
YoY Change	-51.76%	-31.12%	-22.68%
% of Gross Profit
Research & Development	$791.1K	$2.907M	$4.977M
YoY Change	-96.76%	-48.53%	97.79%
% of Gross Profit
Depreciation & Amortization	$7.300K	$7.300K	$7.317K
YoY Change	-94.72%	265.0%	631.7%
% of Gross Profit
Operating Expenses	-$4.390M	$5.406M	$9.382M
YoY Change	-114.44%	-41.73%	14.23%
Operating Profit	$4.390M	-$5.406M	-$9.382M
YoY Change	-114.44%	-41.73%	14.23%
Interest Expense	$863.00	$3.218K	$5.605K
YoY Change	-216.62%	8.94%	8.96%
% of Operating Profit	0.02%
Other Income/Expense, Net	$1.801K	-$2.292K	-$244.8K
YoY Change	-415.96%	11.48%	-146.37%
Pretax Income	$4.391M	-$5.408M	-$9.627M
YoY Change	-114.44%	-41.72%	25.26%
Income Tax
% Of Pretax Income
Net Earnings	$4.391M	-$5.408M	-$9.627M
YoY Change	-114.44%	-41.72%	25.26%
Net Earnings / Revenue
Basic Earnings Per Share	$2.64	-$0.25	-$0.66
Diluted Earnings Per Share	$2.60	-$0.25	-$0.66
COMMON SHARES
Basic Shares Outstanding	41.59M	21.81M	15.54M
Diluted Shares Outstanding	1.626M	21.81M	15.54M

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.657M	$1.155M	$5.695M
YoY Change	-77.02%	-85.7%	-52.64%
Cash & Equivalents	$1.700M	$1.200M	$5.695M
Short-Term Investments
Other Short-Term Assets	$700.1K	$563.7K	$827.1K
YoY Change	139.91%	4.23%	28.61%
Inventory
Prepaid Expenses	$561.5K	$563.7K	$827.1K
Receivables	$192.0K	$70.43K	$28.06K
Other Receivables
Total Short-Term Assets	$2.549M	$1.789M	$6.550M
YoY Change	-66.02%	-79.23%	-50.27%
LONG-TERM ASSETS
Property, Plant & Equipment	$51.16K	$58.48K	$65.79K
YoY Change	-88.6%	-34.48%	6.77%
Goodwill	$1.715M	$1.756M	$1.862M
YoY Change		-11.82%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$55.80K	$34.33K	$34.40K
YoY Change	26.73%	-50.68%	17.65%
Total Long-Term Assets	$2.096M	$2.138M	$2.275M
YoY Change	-57.41%	-58.57%	-52.72%
TOTAL ASSETS
Total Short-Term Assets	$2.549M	$1.789M	$6.550M
Total Long-Term Assets	$2.096M	$2.138M	$2.275M
Total Assets	$4.645M	$3.927M	$8.825M
YoY Change	-62.61%	-71.49%	-50.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.583M	$3.966M	$3.450M
YoY Change	-80.58%	-14.59%	139.46%
Accrued Expenses	$272.3K	$426.2K	$717.5K
YoY Change	18.44%	119.74%	121.57%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$161.9K	$402.8K
YoY Change		16.01%	16.05%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.694M	$17.28M	$14.22M
YoY Change	-64.95%	167.8%	297.68%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$231.3K	$833.3K	$3.850M
YoY Change	-21.78%	191.6%	58492.15%
Total Long-Term Liabilities	$231.3K	$833.3K	$3.850M
YoY Change	-21.78%	191.6%	58492.15%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.694M	$17.28M	$14.22M
Total Long-Term Liabilities	$231.3K	$833.3K	$3.850M
Total Liabilities	$6.925M	$18.12M	$18.07M
YoY Change	-64.29%	168.81%	404.44%
SHAREHOLDERS EQUITY
Retained Earnings	-$164.5M	-$168.9M	-$163.5M
YoY Change		50.36%
Common Stock	$231.00	$2.270K	$2.154K
YoY Change		-72.52%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.280M	-$14.19M	-$9.240M
YoY Change
Total Liabilities & Shareholders Equity	$4.645M	$3.927M	$8.825M
YoY Change	-62.61%	-71.49%	-50.92%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	$4.391M	-$5.408M	-$9.627M
YoY Change	-114.44%	-41.72%	25.26%
Depreciation, Depletion And Amortization	$7.300K	$7.300K	$7.317K
YoY Change	-94.72%	265.0%	631.7%
Cash From Operating Activities	-$4.254M	-$4.586M	-$7.912M
YoY Change	-72.95%	-18.45%	55.95%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change	-100.0%
Cash From Investing Activities	$0.00	$0.00
YoY Change	-100.0%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$8.000M
YoY Change			-11.69%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.772M	76.37K	5.367M
YoY Change	-81.0%	-95.71%	-51.43%
NET CHANGE
Cash From Operating Activities	-4.254M	-4.586M	-7.912M
Cash From Investing Activities	0.000	0.000
Cash From Financing Activities	4.772M	76.37K	5.367M
Net Change In Cash	517.7K	-4.509M	-2.545M
YoY Change	-159.58%	15.19%	-142.58%
FREE CASH FLOW
Cash From Operating Activities	-$4.254M	-$4.586M	-$7.912M
Capital Expenditures	$0.00	$0.00
Free Cash Flow	-$4.254M	-$4.586M
YoY Change	-72.96%	-17.36%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21807333
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7812440
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18693306
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6679918
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.25
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.63
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.82
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.39
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22699812
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14855848
	dei	Entity Registrant Name EntityRegistrantName	First Wave BioPharma, Inc.
	dei	Entity Central Index Key EntityCentralIndexKey	0001604191
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7317
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22699812
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14855848
CY2022Q2	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P63M
CY2021	us-gaap	Impairment Of Intangible Asset Finite Lived Statement Of Income Or Comprehensive Income Extensible Enumeration ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpense
CY2021	us-gaap	Impairment Of Intangible Asset Finite Lived Statement Of Income Or Comprehensive Income Extensible Enumeration ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpense
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-37853
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-4993860
	dei	Entity Address Address Line1 EntityAddressAddressLine1	777 Yamato Road, Suite 502
	dei	Entity Address City Or Town EntityAddressCityOrTown	Boca Raton
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33431
	dei	City Area Code CityAreaCode	561
	dei	Local Phone Number LocalPhoneNumber	589-7020
	dei	Security12b Title Security12bTitle	Common stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	FWBI
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	41590308
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1155009
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8248684
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	70429
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	563661
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1176268
CY2022Q2	us-gaap	Assets Current AssetsCurrent	1789099
CY2021Q4	us-gaap	Assets Current AssetsCurrent	9424952
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	58475
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	73110
CY2022Q2	us-gaap	Goodwill Goodwill	1755870
CY2021Q4	us-gaap	Goodwill Goodwill	1911705
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	289504
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	336197
CY2022Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	34326
CY2021Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	44012
CY2022Q2	fwbi	Assets Noncurrent Excluding Property Plant And Equipment Net AssetsNoncurrentExcludingPropertyPlantAndEquipmentNet	2079700
CY2021Q4	fwbi	Assets Noncurrent Excluding Property Plant And Equipment Net AssetsNoncurrentExcludingPropertyPlantAndEquipmentNet	2291914
CY2022Q2	us-gaap	Assets Assets	3927274
CY2021Q4	us-gaap	Assets Assets	11789976
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	3966363
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2707731
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	426235
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	393253
CY2022Q2	us-gaap	Dividends Payable Current DividendsPayableCurrent	653278
CY2021Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	465361
CY2022Q2	us-gaap	Notes Payable Current NotesPayableCurrent	161909
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	641236
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	62673
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	77989
CY2022Q2	fwbi	Payable Related To Acquisition Current PayableRelatedToAcquisitionCurrent	12000000
CY2021Q4	fwbi	Payable Related To Acquisition Current PayableRelatedToAcquisitionCurrent	8000000
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	13408
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	14818
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	17283866
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12300388
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	248226
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	311138
CY2022Q2	fwbi	Payable Related To Acquisition Long Term PayableRelatedToAcquisitionLongTerm	585045
CY2021Q4	fwbi	Payable Related To Acquisition Long Term PayableRelatedToAcquisitionLongTerm	7000000
CY2022Q2	us-gaap	Liabilities Liabilities	18117137
CY2021Q4	us-gaap	Liabilities Liabilities	19611526
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22699812
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14855848
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	2270
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	1485
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	156166384
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	147305147
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-168939031
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-153904047
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1419486
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1224135
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-14189863
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-7821550
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3927274
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11789976
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2906896
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5647798
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7883413
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8163825
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2498957
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3629090
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6904512
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9326604
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	5405853
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	9276888
	us-gaap	Operating Expenses OperatingExpenses	14787925
	us-gaap	Operating Expenses OperatingExpenses	17490429
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5405853
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-9276888
	us-gaap	Operating Income Loss OperatingIncomeLoss	-14787925
	us-gaap	Operating Income Loss OperatingIncomeLoss	-17490429
CY2022Q2	us-gaap	Interest Expense InterestExpense	3218
CY2021Q2	us-gaap	Interest Expense InterestExpense	2954
	us-gaap	Interest Expense InterestExpense	8823
	us-gaap	Interest Expense InterestExpense	8098
CY2022Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	926
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1065
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	898
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-239301
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1601
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	532353
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2292
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2056
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-247059
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	525856
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-5408145
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-9278944
	us-gaap	Net Income Loss NetIncomeLoss	-15034984
	us-gaap	Net Income Loss NetIncomeLoss	-16964573
CY2022Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-136946
CY2021Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	21840
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-195351
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-112957
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5545091
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9257104
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15230335
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17077530
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-5408145
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-9278944
	us-gaap	Net Income Loss NetIncomeLoss	-15034984
	us-gaap	Net Income Loss NetIncomeLoss	-16964573
	fwbi	Deemed Dividends Preferred Stock Issuances DeemedDividendsPreferredStockIssuances	4507125
CY2021Q2	fwbi	Deemed Dividends Preferred Stock Exchanges DeemedDividendsPreferredStockExchanges	3424205
	fwbi	Deemed Dividends Preferred Stock Exchanges DeemedDividendsPreferredStockExchanges	21008253
CY2022Q2	fwbi	Deemed Dividends On Warrant Modification DeemedDividendsOnWarrantModification	47300
	fwbi	Deemed Dividends On Warrant Modification DeemedDividendsOnWarrantModification	47300
CY2022Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	97125
CY2021Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	26661
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	187917
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	231043
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5552570
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12729810
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-15270201
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-42710994
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21807333
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7812440
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18693306
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6679918
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.63
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.82
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.39
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-9239785
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	317231
CY2022Q2	fwbi	Deemed Dividend Of Series B Preferred Stock DeemedDividendOfSeriesBPreferredStock	-97125
CY2022Q2	fwbi	Warrant Modification WarrantModification	47300
CY2022Q2	fwbi	Deemed Dividend On Warrant Modification DeemedDividendOnWarrantModification	-47300
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	374907
CY2022Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-136946
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-5408145
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-14189863
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	14401687
CY2021Q2	fwbi	Stock Issued During Period Value Exchange Of Preferred Stock StockIssuedDuringPeriodValueExchangeOfPreferredStock	-422
CY2021Q2	fwbi	Adjustments To Additional Paid In Capital Warrant Issued Exchange Of Preferred Stock AdjustmentsToAdditionalPaidInCapitalWarrantIssuedExchangeOfPreferredStock	3424626
	fwbi	Stock Issued During Period Value Exchange Of Preferred Stock StockIssuedDuringPeriodValueExchangeOfPreferredStock	-1431
	fwbi	Adjustments To Additional Paid In Capital Warrant Issued Exchange Of Preferred Stock AdjustmentsToAdditionalPaidInCapitalWarrantIssuedExchangeOfPreferredStock	21009683
	fwbi	Adjustments To Additional Paid In Capital Deemed Dividend Exchange Of Preferred Stock AdjustmentsToAdditionalPaidInCapitalDeemedDividendExchangeOfPreferredStock	21008253
	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	231043
	fwbi	Stock Issued During Period Value Common Stock And Pre Funded Warrants Issued Upon Conversion Of Convertible Securities StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsIssuedUponConversionOfConvertibleSecurities	3
	fwbi	Stock Issued During Period Value Common Stock Pre Funded Warrants And Warrants For Cash Net Of Offering Costs StockIssuedDuringPeriodValueCommonStockPreFundedWarrantsAndWarrantsForCashNetOfOfferingCosts	9059290
CY2021Q2	fwbi	Adjustments To Additional Paid In Capital Deemed Dividend Exchange Of Preferred Stock AdjustmentsToAdditionalPaidInCapitalDeemedDividendExchangeOfPreferredStock	3424205
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	26661
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1174348
CY2021Q2	fwbi	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	282788
CY2021Q2	fwbi	Stock And Warrants Issued During Period Value Issued For Services StockAndWarrantsIssuedDuringPeriodValueIssuedForServices	147811
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	314056
CY2021Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	21840
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-9278944
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	7036924
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-7821550
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	317231
	fwbi	Common Stock And Pre Funded Warrants Issued Upon Exercise Amount CommonStockAndPreFundedWarrantsIssuedUponExerciseAmount	48482
	fwbi	Deemed Dividend Of Series B Preferred Stock DeemedDividendOfSeriesBPreferredStock	-187917
	fwbi	Warrant Modification WarrantModification	47300
	fwbi	Deemed Dividend On Warrant Modification DeemedDividendOnWarrantModification	-47300
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	118999
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	593136
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-195351
	us-gaap	Net Income Loss NetIncomeLoss	-15034984
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-14189863
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-2640693
	fwbi	Stock And Warrants Stock During Period Value Cash Net Of Offering Costs StockAndWarrantsStockDuringPeriodValueCashNetOfOfferingCosts	7105167
	fwbi	Stock Issued During Period Value License StockIssuedDuringPeriodValueLicense	2467648
	fwbi	Adjustments To Additional Paid In Capital Conversion Of Convertible Securities AdjustmentsToAdditionalPaidInCapitalConversionOfConvertibleSecurities	4507125
	fwbi	Deemed Dividend Of Series C Preferred Stock DeemedDividendOfSeriesCPreferredStock	-4507125
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1174348
	fwbi	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	4906630
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1092310
	fwbi	Stock Issued During Period Value Issued Settlement With Former Placement Agent StockIssuedDuringPeriodValueIssuedSettlementWithFormerPlacementAgent	94499
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1086296
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-112957
	us-gaap	Net Income Loss NetIncomeLoss	-16964573
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	7036924
	us-gaap	Net Income Loss NetIncomeLoss	-15034984
	us-gaap	Net Income Loss NetIncomeLoss	-16964573
	us-gaap	Depreciation Depreciation	14635
	us-gaap	Depreciation Depreciation	3014
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	263774
	fwbi	Change In Right Of Use Assets ChangeInRightOfUseAssets	46693
	fwbi	Change In Right Of Use Assets ChangeInRightOfUseAssets	-4855
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	532353
	us-gaap	Share Based Compensation ShareBasedCompensation	593136
	us-gaap	Share Based Compensation ShareBasedCompensation	1086296
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	118999
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1186809
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	70429
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-551489
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-612607
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-715368
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-78228
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-316541
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-9686
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	41676
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1258632
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3424266
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	32982
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-465984
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-1410
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	398838
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12497681
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10696128
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	73928
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-73928
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	7105168
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8289322
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10233638
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	48482
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	4906630
	fwbi	Payment Made Related To License Agreement PaymentMadeRelatedToLicenseAgreement	9000000
	fwbi	Payment Made Related To Acquisition Agreement PaymentMadeRelatedToAcquisitionAgreement	2414955
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	479327
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	412836
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5443522
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12832600
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-7054159
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	2062544
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-39516
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-50194
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8248684
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6062141
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1155009
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8074491
	fwbi	Deemed Dividends Preferred Stock Issuances DeemedDividendsPreferredStockIssuances	4507125
	fwbi	Deemed Dividends Preferred Stock Exchanges DeemedDividendsPreferredStockExchanges	21008253
	fwbi	Deemed Dividend On Warrant Modification DeemedDividendOnWarrantModification	-47300
CY2022Q2	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	187917
CY2021Q2	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	231043
	fwbi	Common Stock Issued Upon Conversion Of Preferred Stock CommonStockIssuedUponConversionOfPreferredStock	-19
	us-gaap	Stock Issued1 StockIssued1	2467649
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1200000
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-168900000
CY2022Q2	fwbi	Working Capital WorkingCapital	15500000
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	29343
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed consolidated financial statements are prepared in conformity with GAAP and include certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements (including goodwill and intangible assets), and the reported amounts of revenue and expense during the reporting period, including contingencies. Accordingly, actual results may differ from those estimates.</p>
CY2021Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	3802745
CY2021Q4	fwbi	Consulting Fees ConsultingFees	104100
CY2022Q2	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	70495
CY2022Q2	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	3800000
CY2021Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	15000
CY2022Q2	fwbi	Consulting Fees ConsultingFees	92124
CY2021Q3	us-gaap	Stock Issued During Period Shares Reverse Stock Splits StockIssuedDuringPeriodSharesReverseStockSplits	10
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Reclassifications </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Certain prior period balance sheet amounts have been reclassified to conform to the fiscal 2022 presentation.</p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist of cash. The Company primarily maintains its cash balances with financial institutions in federally insured accounts in the U.S. The Company may from time to time have cash in banks in excess of FDIC insurance limits. On June 30, 2022, and December 31, 2021, the Company had approximately $0.6 million and $7.5 million, respectively, in one account in the U.S. in excess of these limits. The Company has not experienced any losses to date resulting from this practice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company also has exposure to foreign currency risk as its subsidiary in France has a functional currency in Euros.</p>
CY2022Q2	us-gaap	Cash Uninsured Amount CashUninsuredAmount	600000
CY2021Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	7500000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	14708
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	58475
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	73110
CY2022Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7300
CY2021Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2000
	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P7Y2M12D
CY2021	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	2400000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3000
CY2022Q2	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	161909
CY2021Q4	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	641236
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	87818
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	87818
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3802745
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1450757
CY2021Q4	fwbi	Finite Lived Intangible Assets Impairment FiniteLivedIntangibleAssetsImpairment	2351988
CY2021Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	132000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	264000
CY2021	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	2400000
CY2020Q4	us-gaap	Goodwill Goodwill	2054048
CY2021	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-142343
CY2021Q4	us-gaap	Goodwill Goodwill	1911705
	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-155835
CY2022Q2	us-gaap	Goodwill Goodwill	1755870
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	156465
CY2022Q2	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	263616
CY2021Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	274153
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	426235
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	393253
CY2022Q2	fwbi	Note Payables NotePayables	162000
CY2021Q4	fwbi	Note Payables NotePayables	641000
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q3	us-gaap	Stock Issued During Period Shares Reverse Stock Splits StockIssuedDuringPeriodSharesReverseStockSplits	10
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22699812
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14855848
	fwbi	Deemed Dividend On Warrant Modification DeemedDividendOnWarrantModification	-47000.000
CY2022Q2	fwbi	Deemed Dividend On Warrant Modification DeemedDividendOnWarrantModification	-47000.000
CY2022Q1	fwbi	Stocks Issued During Period Shares Common Stock Pre Funded Warrants And Warrants For Cash Net Of Offering Costs StocksIssuedDuringPeriodSharesCommonStockPreFundedWarrantsAndWarrantsForCashNetOfOfferingCosts	1650000
CY2022Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.375
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8000000.0
CY2022Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.26
CY2022Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2021Q1	fwbi	Stocks Issued During Period Shares Common Stock Pre Funded Warrants And Warrants For Cash Net Of Offering Costs StocksIssuedDuringPeriodSharesCommonStockPreFundedWarrantsAndWarrantsForCashNetOfOfferingCosts	580000
CY2021Q1	fwbi	Pre Funded Warrants To Purchase Of Common Stock PreFundedWarrantsToPurchaseOfCommonStock	205854
CY2021Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2021Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	12.725
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5527390
CY2021Q4	fwbi	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Outstanding And Exercisable ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsOutstandingAndExercisable	9.49
CY2021Q4	fwbi	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Outstanding And Exercisable ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsOutstandingAndExercisable	3.95
	fwbi	Class Of Warrant Or Right Granted ClassOfWarrantOrRightGranted	11927519
	fwbi	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Granted ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted	0.77
	fwbi	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Granted ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted	4.67
	fwbi	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	121639
	fwbi	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Expired ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired	-36.93
	fwbi	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Expired ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExpired	0
	fwbi	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	4848195
	fwbi	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercised ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised	-0.01
	fwbi	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Exercised ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised	-4.67
CY2022Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	12485075
CY2022Q2	fwbi	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Outstanding And Exercisable ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsOutstandingAndExercisable	3.49
CY2022Q2	fwbi	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Outstanding And Exercisable ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsOutstandingAndExercisable	4.18
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2517722
CY2020Q4	fwbi	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Outstanding And Exercisable ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsOutstandingAndExercisable	12.20
CY2020Q4	fwbi	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Outstanding And Exercisable ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsOutstandingAndExercisable	4.04
	fwbi	Class Of Warrant Or Right Granted ClassOfWarrantOrRightGranted	3922426
	fwbi	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Granted ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted	7.78
	fwbi	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Granted ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted	4.88
	fwbi	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	32117
	fwbi	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Expired ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired	-20.07
	fwbi	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Expired ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExpired	0
	fwbi	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	952588
	fwbi	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercised ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised	-5.32
	fwbi	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Exercised ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised	-2.36
CY2021Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5455443
CY2021Q2	fwbi	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Outstanding And Exercisable ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsOutstandingAndExercisable	10.18
CY2021Q2	fwbi	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Outstanding And Exercisable ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsOutstandingAndExercisable	4.38
CY2021Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.26
CY2021Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1350066
CY2021Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	20000
CY2021Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	16.90
CY2021Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P4Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	678392
	fwbi	Class Of Warrant Or Right Grants In Period Weighted Average Grant Date Fair Value ClassOfWarrantOrRightGrantsInPeriodWeightedAverageGrantDateFairValue	1.23
	fwbi	Class Of Warrant Or Right Grants In Period Weighted Average Grant Date Fair Value ClassOfWarrantOrRightGrantsInPeriodWeightedAverageGrantDateFairValue	6.81
CY2022Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1100000
CY2022Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P9Y4M24D
CY2021Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1100000
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	27500
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	27500
	fwbi	Unrecognized Expense UnrecognizedExpense	197000
	fwbi	Unrecognized Expense UnrecognizedExpense	197000
	fwbi	Unrecognized Expense UnrecognizedExpense	197000
	fwbi	Unrecognized Expense UnrecognizedExpense	197000
	fwbi	Class Of Warrant Or Right Redemption Of Warrants Or Rights Threshold Trading Days ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays	20
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	374907
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	314056
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	593136
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1086296
CY2022Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	50000
CY2021Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	57000
	us-gaap	Operating Lease Expense OperatingLeaseExpense	78000
	us-gaap	Operating Lease Expense OperatingLeaseExpense	110000
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y1M6D
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0700
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	41126
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	83691
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	86202
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	88788
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	60593
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	360400
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	49501
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	310899
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14115297
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6591015
CY2022Q2	us-gaap	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	7.70
CY2022Q2	fwbi	Amount Incorrectly Classified As Deemed Dividend AmountIncorrectlyClassifiedAsDeemedDividend	595000
	us-gaap	Defined Contribution Plan Employers Matching Contribution Annual Vesting Percentage DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage	0.06
CY2022Q2	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	29000
CY2021Q2	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	23000
	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	76000
	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	55000
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	6969988
CY2022Q2	fwbi	Class Of Warrant Or Right Redemption Of Warrants Or Rights Threshold Trading Days ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays	30
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	1.00

Files In Submission

Name	View Source	Status
0001410578-22-002519-index-headers.html	Edgar Link	pending
0001410578-22-002519-index.html	Edgar Link	pending
0001410578-22-002519.txt	Edgar Link	pending
0001410578-22-002519-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
fwbi-20220630.xsd	Edgar Link	pending
fwbi-20220630x10q.htm	Edgar Link	pending
fwbi-20220630xex31d1.htm	Edgar Link	pending
fwbi-20220630xex31d2.htm	Edgar Link	pending
fwbi-20220630xex32d1.htm	Edgar Link	pending
fwbi-20220630xex3d1.htm	Edgar Link	pending
fwbi-20220630xex3d1001.jpg	Edgar Link	pending
fwbi-20220630xex3d1002.jpg	Edgar Link	pending
fwbi-20220630xex3d1003.jpg	Edgar Link	pending
fwbi-20220630xex3d1004.jpg	Edgar Link	pending
fwbi-20220630xex3d1005.jpg	Edgar Link	pending
fwbi-20220630xex3d1006.jpg	Edgar Link	pending
fwbi-20220630xex3d1007.jpg	Edgar Link	pending
fwbi-20220630xex3d1008.jpg	Edgar Link	pending
fwbi-20220630xex3d1009.jpg	Edgar Link	pending
fwbi-20220630xex3d1010.jpg	Edgar Link	pending
fwbi-20220630xex3d1011.jpg	Edgar Link	pending
fwbi-20220630xex3d1012.jpg	Edgar Link	pending
fwbi-20220630xex3d1013.jpg	Edgar Link	pending
fwbi-20220630xex3d1014.jpg	Edgar Link	pending
fwbi-20220630xex3d1015.jpg	Edgar Link	pending
fwbi-20220630xex3d1016.jpg	Edgar Link	pending
fwbi-20220630xex3d1017.jpg	Edgar Link	pending
fwbi-20220630xex3d1018.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
fwbi-20220630x10q_htm.xml	Edgar Link	completed
fwbi-20220630xex3d1019.jpg	Edgar Link	pending
fwbi-20220630xex3d1020.jpg	Edgar Link	pending
fwbi-20220630xex3d1021.jpg	Edgar Link	pending
fwbi-20220630xex3d1022.jpg	Edgar Link	pending
fwbi-20220630xex3d1023.jpg	Edgar Link	pending
fwbi-20220630xex3d1024.jpg	Edgar Link	pending
fwbi-20220630xex3d1025.jpg	Edgar Link	pending
fwbi-20220630xex3d1026.jpg	Edgar Link	pending
fwbi-20220630xex3d1027.jpg	Edgar Link	pending
fwbi-20220630xex3d1028.jpg	Edgar Link	pending
fwbi-20220630xex3d1029.jpg	Edgar Link	pending
fwbi-20220630xex3d1030.jpg	Edgar Link	pending
fwbi-20220630xex3d1031.jpg	Edgar Link	pending
fwbi-20220630xex3d1032.jpg	Edgar Link	pending
fwbi-20220630xex3d1033.jpg	Edgar Link	pending
fwbi-20220630xex3d1034.jpg	Edgar Link	pending
fwbi-20220630xex3d1035.jpg	Edgar Link	pending
fwbi-20220630xex3d1036.jpg	Edgar Link	pending
fwbi-20220630xex3d1037.jpg	Edgar Link	pending
fwbi-20220630xex3d1038.jpg	Edgar Link	pending
fwbi-20220630xex3d1039.jpg	Edgar Link	pending
fwbi-20220630xex3d1040.jpg	Edgar Link	pending
fwbi-20220630xex3d1041.jpg	Edgar Link	pending
fwbi-20220630xex3d1042.jpg	Edgar Link	pending
fwbi-20220630xex3d1043.jpg	Edgar Link	pending
fwbi-20220630xex3d1044.jpg	Edgar Link	pending
fwbi-20220630xex3d1045.jpg	Edgar Link	pending
fwbi-20220630xex3d1046.jpg	Edgar Link	pending
fwbi-20220630xex3d1047.jpg	Edgar Link	pending
fwbi-20220630xex3d1048.jpg	Edgar Link	pending
fwbi-20220630xex3d1049.jpg	Edgar Link	pending
fwbi-20220630xex3d1050.jpg	Edgar Link	pending
fwbi-20220630xex3d1051.jpg	Edgar Link	pending
fwbi-20220630xex3d1052.jpg	Edgar Link	pending
fwbi-20220630xex3d1053.jpg	Edgar Link	pending
fwbi-20220630xex3d1054.jpg	Edgar Link	pending
fwbi-20220630xex3d1055.jpg	Edgar Link	pending
fwbi-20220630xex3d1056.jpg	Edgar Link	pending
fwbi-20220630xex3d1057.jpg	Edgar Link	pending
fwbi-20220630xex3d1058.jpg	Edgar Link	pending
fwbi-20220630xex3d1059.jpg	Edgar Link	pending
fwbi-20220630xex3d1060.jpg	Edgar Link	pending
fwbi-20220630xex3d1061.jpg	Edgar Link	pending
fwbi-20220630xex3d1062.jpg	Edgar Link	pending
fwbi-20220630xex3d1063.jpg	Edgar Link	pending
fwbi-20220630xex3d1064.jpg	Edgar Link	pending
fwbi-20220630xex3d1065.jpg	Edgar Link	pending
fwbi-20220630xex3d1066.jpg	Edgar Link	pending
fwbi-20220630xex3d1067.jpg	Edgar Link	pending
fwbi-20220630xex3d1068.jpg	Edgar Link	pending
fwbi-20220630xex3d1069.jpg	Edgar Link	pending
fwbi-20220630xex3d1070.jpg	Edgar Link	pending
fwbi-20220630xex3d1071.jpg	Edgar Link	pending
fwbi-20220630xex3d1072.jpg	Edgar Link	pending
fwbi-20220630xex3d1073.jpg	Edgar Link	pending
fwbi-20220630xex3d1074.jpg	Edgar Link	pending
fwbi-20220630xex3d1075.jpg	Edgar Link	pending
fwbi-20220630xex3d1076.jpg	Edgar Link	pending
fwbi-20220630xex3d1077.jpg	Edgar Link	pending
fwbi-20220630xex3d1078.jpg	Edgar Link	pending
fwbi-20220630xex3d1079.jpg	Edgar Link	pending
fwbi-20220630xex3d1080.jpg	Edgar Link	pending
fwbi-20220630xex3d1081.jpg	Edgar Link	pending
fwbi-20220630xex3d1082.jpg	Edgar Link	pending
fwbi-20220630xex3d1083.jpg	Edgar Link	pending
fwbi-20220630xex3d1084.jpg	Edgar Link	pending
fwbi-20220630xex3d1085.jpg	Edgar Link	pending
fwbi-20220630xex3d1086.jpg	Edgar Link	pending
fwbi-20220630xex3d1087.jpg	Edgar Link	pending
fwbi-20220630xex3d1088.jpg	Edgar Link	pending
fwbi-20220630xex3d1089.jpg	Edgar Link	pending
fwbi-20220630xex3d1094.jpg	Edgar Link	pending
fwbi-20220630xex3d1095.jpg	Edgar Link	pending
fwbi-20220630xex3d1096.jpg	Edgar Link	pending
fwbi-20220630xex3d1097.jpg	Edgar Link	pending
fwbi-20220630xex3d1098.jpg	Edgar Link	pending
fwbi-20220630xex3d1099.jpg	Edgar Link	pending
fwbi-20220630xex3d1100.jpg	Edgar Link	pending
fwbi-20220630xex3d1101.jpg	Edgar Link	pending
fwbi-20220630xex3d1102.jpg	Edgar Link	pending
fwbi-20220630xex3d1103.jpg	Edgar Link	pending
fwbi-20220630xex3d1104.jpg	Edgar Link	pending
fwbi-20220630xex3d1105.jpg	Edgar Link	pending
fwbi-20220630xex3d1106.jpg	Edgar Link	pending
fwbi-20220630xex3d1107.jpg	Edgar Link	pending
fwbi-20220630xex3d1108.jpg	Edgar Link	pending
fwbi-20220630xex3d1110.jpg	Edgar Link	pending
fwbi-20220630xex3d2.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
fwbi-20220630_def.xml	Edgar Link	unprocessable
fwbi-20220630_pre.xml	Edgar Link	unprocessable
fwbi-20220630_lab.xml	Edgar Link	unprocessable
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
fwbi-20220630_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ENTO
Entero Therapeutics Inc Stock $ento

2022 Q3 Form 10-Q Financial Statement

#000141057822002519 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENTO Entero Therapeutics Inc Stock $ento

2022 Q3 Form 10-Q Financial Statement

#000141057822002519 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENTO
Entero Therapeutics Inc Stock $ento